On April 7, 2015, an objection to the disclosure statement with respect to a plan of reorganization or liquidation was filed in the bankruptcy case of Dendreon Corporation and its affiliates.
The filing was assigned docket number 552 and is described on the court’s official docket as follows:
Limited Objection of GlaxoSmithKline LLC to (I) the Debtors’ Disclosure Statement and (II) the Debtors’ Motion for Order Approving the Disclosure Statement (related document(s), ) Filed by GlaxoSmithKline LLC (Attachments: # (1) Exhibit A # (2) Certificate of Service) (Patterson, Morgan)
Dendreon Corporation filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on November 10, 2014. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 14-12515. The bankruptcy case is currently assigned to United States Bankruptcy Judge Peter Walsh. The law firm of Skadden, Arps, Slate, Meagher & Flom LLP is acting as lead bankruptcy counsel to Dendreon Corporation in the bankruptcy case.